Abstract
INTRODUCTION Amyloid-β (Aβ) and tau are brain hallmarks of Alzheimer’s disease (AD) also present in blood as soluble biomarkers or encapsulated in extracellular vesicles (EVs). Our goal was to assess how soluble plasma biomarkers of AD pathology correlate with number and content of EVs.
METHODS Single-molecule enzyme-linked assays were used to quantify Aβ42/40 and tau in plasma samples and neurally-derived EVs (NDEVs) from a cohort of APOE ε4– and APOE ε4+ cognitively normal individuals (CN) and AD patients.
RESULTS Soluble plasma Aβ42/40 ratio is decreased in AD patients compared to CN individuals. The amount and content (Aβ40, Aβ42, tau) of plasma NDEVs were similar between groups. Quantity of soluble biomarkers were negatively correlated to NDEVs number only in CN individuals.
DISCUSSION Soluble Aβ42/40 ratio is the most robust AD plasma biomarker. Analysis of NDEVs and their content pointed toward peculiar mechanisms of Aβ release in AD.
Institutional Review Board Statement The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Clinics Saint-Luc University Hospital, 1200 Brussels, Belgium (UCL-2022-473; UCL-2016-121; UCL-2018-119).
HIGHLIGHTS
The number of neurally-derived extracellular vesicles (NDEVs) in plasma is not a stand-alone biomarker for Alzheimer’s disease (AD).
Plasma levels of Aβ42, Aβ40 and total-tau are strongly negatively correlated with NDEVs concentration in cognitively normal (CN) individuals.
In AD patients, this correlation is lost, highlighting a shift in the mechanism underpinning the production and the release of these biomarkers in pathological conditions.
The soluble plasma amyloid-β (Aβ) 42/40 ratio is the most robust biomarker to discriminate between AD patients and CN individuals, as it normalizes for the number of NDEVs.
RESEARCH IN CONTEXT
Systematic review: The authors reviewed PubMed for plasma biomarkers and neurally-derived extracellular vesicles (NDEVs) in AD. While many studies focus on soluble plasma AD biomarkers like Aβ42/40 ratio or tau protein variants, less explore NDEVs. This study investigates NDEVs as potential AD biomarkers and their correlation with soluble plasma biomarkers.
Interpretation: Our study confirms decreased soluble Aβ42 and increased soluble total-tau in AD patients, with soluble Aβ40 indicating elevated Aβ production in AD versus CN individuals. The Aβ42/40 ratio is a robust AD biomarker. CN individuals with AD risk (APOE ε4+) show decreased ratios without symptoms. Plasma NDEVs remain consistent across ages and between AD and CN individuals, but correlations with soluble plasma biomarkers suggest altered Aβ processes in AD.
Future directions: Further research on independent cohorts can confirm our findings and assess whether plasma Aβ and tau need correction by NDEVs for better AD risk identification in CN populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Belgian Fund for Scientific Research (grant numbers ASP40001844, CCL40010417, FNRS J.0106.22); the Fonds de la Recherche Fondamentale Strategique - Walloon Excellence in Life Sciences and Biotechnology (grant number 40010035); the SAO-FRA Alzheimer s Research Foundation (grant number SAO-FRA 2018/0025); the UCLouvain Action de Recherche Concertee (grant number ARC21/26-114); the Fondation Louvain; the Fondation St Luc, the Fonds europeen de developpement regional and the Queen Elisabeth Medical Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Ethics Committee of Clinics Saint-Luc University Hospital, 1200 Brussels, Belgium gave ethical approval for this work (UCL-2022-473; UCL-2016-121; UCL-2018-119).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors